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In order to ensure most Chinese patients, particularly in the population with relatively low incomes, have
access to safe, low cost, effective and quality-assured medicines, a number of “stand-alone” biological
products, which have good quality, safety and efﬁcacy have been marketed in China. Many countries and
regions’ regulatory agencies are actively engaging in the development of bio-similar guidance and
documents, which is being coordinated by WHO. As a major developing country of new drug develop-
ment, China is now working hard to promote the process of new similar biotherapeutic products (SBPs)
approval and also actively involved in developing and updating technical documents.
 World Health Organization 2011. All rights reserved. The World Health Organization has granted the
Publisher permission for the reproduction of this article.1. Introduction
China is the most populous and largest developing country in
the world. Hundreds of millions of people with low incomes who
need abundant, available and affordable medicines are a huge
potential market for similar biotherapeutic products (SBPs). For
decades, Chinese drug regulatory agencies have beenworking hard
to establish and improve the approval documents and technical
guidelines for biological products consistent with national condi-
tions and scientiﬁc principles. China’s efforts have been not only to
assure the quality and efﬁcacy of licensed products, but also to
prompt bio-industry development. In the Chinese market, the
available biological products have played an extremely important
role in clinical treatment. Over the past ten years, there have been
no serious adverse events related to the quality of these biological
products reported in China. In recent years, China has actively
participated in WHO’s conferences focusing on guidance develop-
ment for SBPs. From the authors’ personal views, below is
a summary of the current situation in China concerning SBP regu-
lation and future perspectives.
2. Overview of the current regulatory situation in China
2.1. Regulations and guidelines
As of now, there are no speciﬁed regulations for SBPs in China.
None of the marketed biological products have been approved
using the term “SBP”. But some of the regulations included infax: þ86 (0)10 67018094.
C. Liang), wangjz@nicpbp.org.
ll rights reserved. The World Healthappendix 3 of “Provisions for Drug Registration (SFDA Order 28)”
are related to ‘non-innovator products’. Part one of the Appendix 3
is the “Registration Categories and document requirement for
Biotherapeutic Products” which includes ﬁfteen categories. Three
of which are related to ‘non-innovator product’ as follows:
 Category 7: Biological products already marketed overseas but
not marketed locally.
 Category 10: Products with a manufacturing process different
from the already marketed one (such as use of different
expression system, host cells etc).
 Category 15: Biological products with National Standards.2.2. Requirements for the registration of ‘non-innovator products’
2.2.1. Quality
 Fullcharacterizationisrequiredforallbiologicalproducts.Keyquality
attributes include physicochemical properties such as structure,
biological activity and purity, including identiﬁcation of impurities.
 For ‘non-innovator products’, comprehensive dossiers describing
quality comparability should be submitted. The gene and amino
acid sequence, the production process, the biological activity, the
ﬁnal product formulation and the speciﬁcation of quality control of
theSBPs shouldbebasicallyconsistentwith themarketedproducts.2.2.2. Non-clinical evaluation
Generally, only one relevant animal is needed for toxicology
testing. Normally only one month of study is required for theOrganization has granted the Publisher permission for the reproduction of this article.
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pharmacodynamic studies. If similarity with the marketed
product has been thoroughly veriﬁed, non-clinical studies can be
reduced.
Although the requirements permit smaller non-clinical studies
for SBPs, most ‘non-innovator products’ having been marketed or
approved for clinical trial have actually been subjected to complete
non-clinical evaluation.
2.2.3. Clinical trials
Complete clinical trials, as are required for new drugs are
necessary for the products included in categories 7 and 10. Only
phase III clinical trials are needed for the products included in
category 15. If relevant differences are found in the quality,
a complete clinical trial is also required.2.3. Examples of domestic ‘non-innovator products’ marketed in
China
 Cytokines: Such as interleukins (IL), interferons (IFN), eryth-
ropoietin (EPO), granulocyte colony stimulating factor (GCSF),Fig. 1. Comparison of rh-GH determined by MALDI-TOF. A. Mass spectrum of the European
product, the mass MW is 22118.413. C. Mass spectrum of the mixture of the EU standard agranulocyte/macrophage colony stimulating factor (GM-
CSF), etc.
 Hormones: Such as recombinant human insulin (rh-Insulin)
and its analogues, recombinant human growth hormone (rh-
GH), recombinant human parathormone1-34 (rh-PTH1-34),
recombinant human follicle stimulating hormone (rh-FSH), etc.
 Enzymes: Such as streptokinase (SK), staphylokinase (SAK),
recombinant urate oxidase (r-UOX), etc.
 Antibodies: Such as recombinant humanized CD25monoclonal
antibody, recombinant humanized CD11a monoclonal anti-
body and TNFR-Ig fusion protein.2.4. The current situation with ‘non-innovator products’ in China
 Although comparative evaluation is required for licensure of
‘non-innovator product’, few applicants in China can offer
a complete data package for head-to-head comparison.
Therefore, most marketed ‘non-innovator products’ are “Stand-
alone”, whose registration information required is the same as
for new products without thorough comparability studies.rh-GH standard, the mass MW is 22119.793. B. Mass spectrum of the domestic rh-GH
nd the domestic rh-GH product, the mass MW is 22119.344.
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and GCSF, may be produced by many different manufacturers
simultaneously. Although in the past ten years, the situation of
having multi suppliers for one product has had beneﬁts for
lowering the price and ensuring the availability of these ‘non-
innovator products’, it has also reduced the proﬁts and limited
thedevelopment of ‘non-innovatorproducts’bymanufacturers.
 Up to now, there have not been any detailed requirements for
the reference biotherapeutic product (RBP) in China.
 In recent years, the market opportunity for developing ‘non-
innovator products’ for the relative simple biological products
has decreased. The need for the innovative complex ‘non-
innovator products’, such as glycoproteins, therapeutic anti-
bodies and PEG modiﬁed proteins, has gradually increased.
This means that it is more difﬁcult to carry out the compara-
bility exercise for such products. Therefore, there is an urgent
demand for guidelines on developing and evaluating such
‘non-innovator products’.
 Often, experience with state-of-art technologies is limited. For
example, comparative pharmacodynamic studies cannot be
required as a general requirement because of the limited
technical knowledge of PK/PD.Fig. 2. Comparison of rh-GH using capillary electrophoresis (CE). A. Saizen. B. Domes3. On-going efforts of Chinese NRA
3.1. Following WHO guidelines in practice
With the guidance on ‘similar biological medicinal products’
containing Somatropin, Insulin, IFN, GCSF, and EPO published by
EMA, and the “Guideline on Evaluation of Similar Biotherapeutic
Products (SBPs)” published by WHO in recent years, the Chinese
NRA has made great efforts in establishing the science basis and
evaluating principles for the licensing of SBPs in China. These
include:
 Requirements for the comparability exercise for new ‘non-inno-
vator products’ are being increasingly strengthened. Compre-
hensive comparisons of qualityare extensively required especially
for complex macromolecules including glycoproteins, PEG modi-
ﬁed proteins, antibodies and some multi-subunit proteins, etc.
 Actively joining and organizing WHO seminars and academic
symposia related to SBPs.
 Taking full advantages of the regulatory resources and evalu-
ation experience to keep training the manufacturers to
understand the content and rationale of the new guidelinestic rh-GH product. C. A mixture of the Saizen and the domestic rh-GH product.
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based on the comparative approach.
 Strengthening the documentary requirements for the phar-
macy section and developing technical guidelines for PK/PD for
‘non-innovator products’.
3.2. Developing a Chinese guideline for SBPs
Directly led by the SFDA, a group of NRA’s ofﬁcers and experts
has been organized to prepare the Chinese guideline for SBPs. The
future guideline will be drafted based on basic scientiﬁc principles
and considering both the local situation in China and the general
WHO framework.
3.3. Quality assessment being carried out by NIFDC
 Many divisions of NIFDC are actively conducting the compa-
rability assessment of the quality of new ‘non-innovator
products’ and carrying out comparability studies for some ofFig. 3. Comparison of an SBP and RBP rh-FSH using IEF PAGE. A. IEF-PAGE proﬁles of a dom
20 mg/lane. B. Peptide mapping of the RBP and SBP. These were trypsin treated after removthe marketed ‘non-innovator products’ which were licensed
using the route for new drug applications.
 NIFDC is continuing efforts aimed at developing advanced
analyticalmethods for the quality control of biological products.
 Biological products manufacturers are being motivated to
strengthen the safety evaluation for impurities and related
substances produced during processing and/or storage.
 Methods for obtaining some RBPs for quality comparability
exercises by puriﬁcation from original preparations are being
developed.
 Opportunities to be involved in collaborative studies aimed at
producing international standards sponsored by WHO are
being actively encouraged.4. Examples of quality evaluation for being developed SBPs in
China
Some examples of comparability exercises in quality assessment
for SBPs and RBPs which have been carried out by NIFDC or
manufacturers are described below.estic product (SBP) and a Reference product (RBP). Sample volume is approximately
ing the sugar chain.
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The ﬁrst rh-GH was marketed in China in 1998. Until recently,
there were several rh-GH products licensed in China, which were
produced by different domestic manufacturers. Comparability data
is shown for some quality characteristics of the developing
domestic rh-GH product and the somatropin standard of the EP or
Serono product Saizen.
According to Fig. 1, the molecular weigh of the rh-GH produced
by Chinese domestic manufacturer is basically the same as the EP
somatropin standard. No additional mass peaks different from
those found in the individual samples have been detected in the
mass spectrum of the mixture sample. Furthermore, Fig. 2 showed
that the proﬁles of the impurities tested by CE are similar for the
domestic rh-GH product and the Serono product Saizen. There are
no additional peaks of impurities seen in the proﬁle of the Chinese
rh-GH compared to that of Saizen. Based on the comparability
exercise, it can be concluded that the rh-GH marketed in China is
similar to the brand product in quality.
4.2. Recombinant human follicle stimulating hormone (rh-FSH)
A domestic rh-FSH product has been approved for conducting
a clinical trail in China. Because the heterogeneity in charge and the
structure are key attributes of glycoproteins, isoelectric focusing-
PAGE (IEF) and peptide mapping were picked as examples of
techniques to demonstrate the similarities between the Chinese
domestic rh-FSH product and the originator product. The RBP
shown below is the rh-FSH sample puriﬁed from Gonal-F
produced by Serono and the SBP is the bulk product produced by
a Chinese manufacturer.
As shown in Fig. 3A, the proﬁle of bands produced using the
rh-FSH produced by the Chinese domestic manufacturer were
similar to that found for the Serono product when analyzed using
IEF. No signiﬁcant differences were detected between the RBP and
the SBP in the proﬁles of their peptide maps. That is to say, the
rh-FSH product produced in China is similar to the originator
product.5. Discussion and suggestion
5.1. A relatively ﬂexible guideline for SBPs should be considered
There are no essential differences between China and elsewhere
in terms of quality control and evaluation of SBPs. We propose the
use of comprehensive comparability exercises as long as RBPs are
available. A ﬂexible approach can be adopted regarding pre-clinical
and toxicological studies; for instance, wewould conduct extensive
studies depending on literature reports. Since the clinical modes of
action and indications of the originators are well understood, these
could be picked for initial development.
Intellectual property issues and technical barriers often make it
difﬁcult for developing countries to obtain reference branded
products. Therefore, we suggest that the ‘non-innovator products’
which are already licensed or registered in China can be chosen as
RBPs on condition that their quality and safety have been thor-
oughly established by the data collected from the marketplace.
5.2. Alternative approaches should be allowed in the licensing for
SBPs
For some products with complex and heterogeneous structure
such as glycoproteins, therapeutic antibodies and PEG modiﬁed
protein, the requirement for a head-to-head comparison is not
currently adopted in China and some other developing countries
due to the extreme difﬁcult in obtaining the RBPs. We propose
alternative approaches for these kinds of products so that devel-
opment of biological products is not hindered. Given that the
molecular structure of the product has been deﬁned, it is not
necessary for a new applicant to submit a full data package of
a head-to-head analysis. Comparison of speciﬁcations and the key
quality characteristics with the RBP should be enough. But
complete clinical trials should be required to ensure the safety and
the efﬁcacy of these products.
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